Welcome to LookChem.com Sign In|Join Free

CAS

  • or

127985-74-4

Post Buying Request

127985-74-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 2-[(4-isothiocyanatophenyl)methyl]-

    Cas No: 127985-74-4

  • No Data

  • No Data

  • No Data

  • BOC Sciences
  • Contact Supplier

127985-74-4 Usage

Uses

p-SCN-Bn-DOTA, is a Bifunctional chelator, that can be used in the preparation of gadolinium complexes as MRI blood contrast agents.

Check Digit Verification of cas no

The CAS Registry Mumber 127985-74-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,7,9,8 and 5 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 127985-74:
(8*1)+(7*2)+(6*7)+(5*9)+(4*8)+(3*5)+(2*7)+(1*4)=174
174 % 10 = 4
So 127985-74-4 is a valid CAS Registry Number.

127985-74-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-[4,7,10-tris(carboxymethyl)-6-[(4-isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

1.2 Other means of identification

Product number -
Other names UNII-13KT123BYW

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:127985-74-4 SDS

127985-74-4Upstream product

127985-74-4Downstream Products

127985-74-4Relevant articles and documents

Prevention of systemic toxicity during radioimmunotherapy for intravascularly disseminated cancers

-

, (2008/06/13)

The present invention provides a method to target delivery of antibody constructs radiolabeled with an alpha-particle emitting radionuclide to intravascularly disseminated tumor cells while minimizing systemic toxicity. Targeted delivery of a construct specific for a protein expressed on the tumor cells in combination with rapid clearance of intravascular non-targeted radiolabeled antibody construct minimizes alpha particle emissions from the radionuclide and its alpha-particle emitting decay intermediates to non-targeted cells.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 127985-74-4